Registry update — unassessed
Pharmacokinetics, Safety, and Efficacy of Fisetin - A Phase I and Pilot Phase IIa Study
Trial registry update: RECRUITING. No results reported in the supplied registry record.
RCTRoutine significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: May 19, 2026 · Discovered: Sep 15, 2026 · Assessed: — · Historical research backfill
What it does not prove
- The abstract reports only planned study design and rationale, not actual findings—no efficacy results, safety outcomes, or pharmacokinetic data are stated. Enrollment and completion numbers are not provided, so it is unclear whether the trial was fully conducted. No evidence of whether fisetin actually reduced senescent cells, inflammation, or improved health in the study participants is presented.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- 3 months
- Population
- Healthy volunteers and older patients with multiple chronic diseases
- Primary outcome
- Pharmacokinetics (absorption and metabolism), safety, and efficacy of fisetin
- Effect size
- —
- Significance
- Not reported
- Journal
- Ove Andersen
- Published
- May 19, 2026
Sources
Primary source
- Ove Andersen ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
The accumulation of senescent cells with age is a central mechanism that contributes to the development of chronic diseases, primarily by driving systemic chronic inflammation.
Senolytic compounds such as fisetin can selectively target senescent cells for elimination and reduce multiple age-related pathologies in animal models.
We will conduct a clinical trial in healthy volunteers and older patients with multiple chronic diseases.
The participants will receive fisetin or placebo for two days, after which they will be examined at regular intervals for up to three months.
We will investigate how fisetin is absorbed and metabolized by the body, and whether fisetin is safe.
We will also identify methods to best measure the effect of fisetin on chronic inflammation, senescent cells, and general health.
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.